Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Importance: Controversy exists regarding the safety of testosterone replacement therapy (TRT) following recent reports of an increased risk of adverse cardiovascular events. Objective: To investigate the association between TRT and cardiovascular outcomes in men with androgen deficiency. Design, Setting, and Participants: A retrospective cohort study was conducted within an integrated health care delivery system. Men at least 40 years old with evidence of androgen deficiency either by a coded diagnosis and/or a morning serum total testosterone level of less than 300 ng/dL were included. The eligibility window was January 1, 1999, to December 31, 2010, with follow-up through December 31, 2012. Exposures: Any prescribed TRT given by injection, orally, or topically. Main Outcomes and Measures: The primary outcome was a composite of cardiovascular end points that included acute myocardial infarction (AMI), coronary revascularization, unstable angina, stroke, transient ischemic attack (TIA), and sudden cardiac death (SCD). Multivariable Cox proportional hazards models were used to investigate the association between TRT and cardiovascular outcomes. An inverse probability of treatment weight, propensity score methodology, was used to balance baseline characteristics. Results: The cohorts consisted of 8808 men (19.8%) ever dispensed testosterone (ever-TRT) (mean age, 58.4 years; 1.4% with prior cardiovascular events) and 35 527 men (80.2%) never dispensed testosterone (never-TRT) (mean age, 59.8 years; 2.0% with prior cardiovascular events). Median follow was 3.2 years (interquartile range [IQR], 1.7-6.6 years) in the never-TRT group vs 4.2 (IQR, 2.1-7.8) years in the ever-TRT group. The rates of the composite cardiovascular end point were 23.9 vs 16.9 per 1000 person-years in the never-TRT and ever-TRT groups, respectively. The adjusted hazard ratio (HR) for the composite cardiovascular end point in the ever-TRT group was 0.67 (95% CI, 0.62-0.73. Similar results were seen when the outcome was restricted to combined stroke events (stroke and TIA) (HR, 0.72; 95% CI, 0.62-0.84) and combined cardiac events (AMI, SCD, unstable angina, revascularization procedures) (HR, 0.66; 95% CI, 0.60-0.72). Conclusions and Relevance: Among men with androgen deficiency, dispensed testosterone prescriptions were associated with a lower risk of cardiovascular outcomes over a median follow-up of 3.4 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Adverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Doubly robust estimation of causal effects
Funk, M. J., Westreich, D., Wiesen, C., Stürmer, T., Brookhart, M. A., & Davidian, M. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwq439 · Cited by 1,158 · cited 1×
“The approach, combiningoutcome regression afterweighting by the propensity score, is called “doubly robust” estimation.(27) The value of this approach is that the effect estimator is still robust to misspecification of the IPTW model or main regressionmodel.”
MethodVigen, R. (2013) · JAMA · doi:10.1001/jama.2013.280386 · Cited by 1,003 · cited 1×
“The results of this study are counter to 2 other observational studies that found a higher risk of adverse CV outcomes inpatients receivingTRT.(6,7)Vigenetal(6) selectedapopulationofmenwith lowtestosterone levelswhohadundergone coronary angiography and found that the risk of adverse CV outcomes was elevated (HR, 1.”
ResultEffects of Testosterone Treatment in Older Men
Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506119 · Cited by 890
Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men
Finkle, W. D., Greenland, S., Ridgeway, G. K., Adams, J. L., Frasco, M. A., Cook, M. B., Fraumeni, J. F., & Hoover, R. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085805 · Cited by 735 · cited 3×
“The results of this study are counter to 2 other observational studies that found a higher risk of adverse CV outcomes inpatients receivingTRT.(6,7)Vigenetal(6) selectedapopulationofmenwith lowtestosterone levelswhohadundergone coronary angiography and found that the risk of adverse CV outcomes was elevated (HR, 1.”
BackgroundResultSrinivas-Shankar, U., Roberts, S. A., Connolly, M. J., O'Connell, M. D. L., Adams, J. E., Oldham, J. A., & Wu, F. C. W. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1251 · Cited by 629
Jones, T. H., Arver, S., Behre, H. M., Buvat, J., Meuleman, E., Moncada, I., Morales, A. M., Volterrani, M., Yellowlees, A., Howell, J. D., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1233 · Cited by 548
Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study
Corona, G., Rastrelli, G., Monami, M., Guay, A., Buvat, J., Sforza, A., Forti, G., Mannucci, E., & Maggi, M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0447 · Cited by 435
Heufelder, A. E., Saad, F., Bunck, M. C., & Gooren, L. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.007005 · Cited by 349 · cited 1×
“34,35 Inaddition,TRThasbeen associated with reductions in total body weight, increases in lean body mass, and decreased body mass index.(34,36,37) These data lend support to the findings that TRT is associated with lower rates of adverse CV outcomes in androgendeficient men.”
ResultTrends in androgen prescribing in the United States, 2001 to 2011
Baillargeon, J., Urban, R. J., Ottenbacher, K. J., Pierson, K. S., & Goodwin, J. S. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6895 · Cited by 336 · cited 1×
“It hasbeen reported that 25%to40%ofmen receiving testosteroneprescriptionsdonothavebaseline testosterone levelsmeasured.(38,39)The lack of baseline testosterone testing in patients receiving TRT is a concern.”
BackgroundCorona, G., Maseroli, E., Rastrelli, G., Isidori, A. M., Sforza, A., Mannucci, E., & Maggi, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.950653 · Cited by 297
Svartberg, J., Agledahl, I., Figenschau, Y., Sildnes, T., Waterloo, K., & Jorde, R. (2008) · International Journal of Impotence Research · doi:10.1038/ijir.2008.19 · Cited by 160
Cited by
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00229 · Cited by 1,736
van Zanten, A. R. H., De Waele, E., & Wischmeyer, P. E. (2019) · Critical Care · doi:10.1186/s13054-019-2657-5 · Cited by 345
Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies
Corona, G., Rastrelli, G., Di Pasquale, G., Sforza, A., Mannucci, E., & Maggi, M. (2018) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2018.04.641 · Cited by 138
Causal Link Between Vitamin D and Total Testosterone in Men: A Mendelian Randomization Analysis
Chen, C., Zhai, H., Cheng, J., Weng, P., Chen, Y., Li, Q., Wang, C., Xia, F., Wang, N., & Lu, Y. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01874 · Cited by 42
Al-Salihy, A. A.-R. S. (2024) · Frontiers in Reproductive Health · doi:10.3389/frph.2024.1438049 · Cited by 5
Metadata
- Authors
- Cheetham, T. C., An, J., Jacobsen, S. J., Niu, F., Sidney, S., Quesenberry, C. P., & VanDenEeden, S. K.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2017-04-01
- Volume
- 177
- Issue
- 4
- Pages
- 491
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2592216550
- Cited by
- 171
- References
- 14
- FWCI
- 19.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.